Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbCellera Biologics Inc.ABCL · Entity 4118 | Director | August 18, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbCellera Biologics Inc.
Report date August 18, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 251,000 |
Reported balance
After 2026-08-18 transaction · row 1
1 source rowRow 1 · 2026-08-18 · Purchase · Acquired 10,000 · Balance 251,000 |
| Common SharesSEC Table I · non-derivative | IndirectBy Spouse | 5,000 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2026 Filed Aug 18, 2026 18:45 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 10,000 | $11.03 | $110,300.00 |
DisclosureSEC source: 0001834423-26-000008 · wk-form4_1787078721.xml · nonDerivative · entry 1 Montalbano John S. · CIK 0001834423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,000 Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 17:02 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantShare option (right to buy) · Derivative | 111,701 | $0.00 Strike: $5.27 | $0.00 |
DisclosureSEC source: 0001834423-26-000006 · wk-form4_1781283746.xml · derivative · entry 1 Montalbano John S. · CIK 0001834423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,141,544 Underlying: Common Shares · 111,701 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable at the 2027 Annual General Meeting, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| May 14, 2026 Filed May 18, 2026 16:09 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 20,000 | $4.77 | $95,400.00 |
DisclosureSEC source: 0001834423-26-000004 · wk-form4_1779120582.xml · nonDerivative · entry 1 Montalbano John S. · CIK 0001834423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,000 Read SEC document |
| November 26, 2025 Filed Nov 26, 2025 19:58 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 50,000 | $3.57 | $178,460.00 |
DisclosureSEC source: 0001834423-25-000004 · wk-form4_1764187098.xml · nonDerivative · entry 1 Montalbano John S. · CIK 0001834423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,000 Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 21:32 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantShare option (right to buy) · Derivative | 238,864 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001628280-25-031647 · wk-form4_1750109513.xml · derivative · entry 1 Montalbano John S. · CIK 0001834423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,029,843 Underlying: Common Shares · 238,864 shares Expires 2035-06-12 F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable at the 2026 Annual General Meeting, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| March 10, 2025 Filed Mar 10, 2025 21:11 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 25,000 | $2.30 | $57,500.00 |
DisclosureSEC source: 0001628280-25-011750 · wk-form4_1741641056.xml · nonDerivative · entry 1 Montalbano John S. · CIK 0001834423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,000 Read SEC document |
| March 06, 2025 Filed Mar 7, 2025 20:32 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 60,000 | $2.34 | $140,568.00 |
DisclosureSEC source: 0001628280-25-011254 · wk-form4_1741379514.xml · nonDerivative · entry 1 Montalbano John S. · CIK 0001834423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,000 Read SEC document |
| June 21, 2024 Filed Jun 24, 2024 22:15 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantShare option (right to buy) · Derivative | 163,934 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001628280-24-029666 · wk-form4_1719267313.xml · derivative · entry 1 Montalbano John S. · CIK 0001834423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 790,979 Underlying: Common Shares · 163,934 shares Expires 2034-06-21 Read SEC document |
| November 08, 2023 Filed Nov 8, 2023 20:29 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 10,000 | $4.46 | $44,600.00 |
DisclosureSEC source: 0001703057-23-000042 · wk-form4_1699475382.xml · nonDerivative · entry 2 Montalbano John S. · CIK 0001834423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,000 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $4.45 to $4.46. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2023 Filed Nov 8, 2023 20:29 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 20,000 | $4.64 | $92,800.00 |
DisclosureSEC source: 0001703057-23-000042 · wk-form4_1699475382.xml · nonDerivative · entry 1 Montalbano John S. · CIK 0001834423 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,000 Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 17:30 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantShare option (right to buy) · Derivative | 47,231 | $0.00 Strike: $13.18 | $0.00 |
DisclosureSEC source: 0001209191-22-059578 · doc4.xml · derivative · entry 1 Montalbano John S. · CIK 0001834423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 627,045 Underlying: Common Shares · 47,231 shares Expires 2032-12-01 Read SEC document |
| March 04, 2022 Filed Mar 4, 2022 21:51 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 10,000 | $8.54 | $85,400.00 |
DisclosureSEC source: 0001209191-22-016327 · doc4.xml · nonDerivative · entry 1 Montalbano John S. · CIK 0001834423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 17:06 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 20,000 | $9.05 | $181,000.00 |
DisclosureSEC source: 0001209191-22-015227 · doc4.xml · nonDerivative · entry 1 Montalbano John S. · CIK 0001834423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 18:15 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantShare option (right to buy) · Derivative | 45,532 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001209191-21-068956 · doc4.xml · derivative · entry 4 Montalbano John S. · CIK 0001834423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 579,814 Underlying: Common Shares · 45,532 shares Expires 2031-12-07 Read SEC document |
| August 27, 2021 Filed Dec 10, 2021 18:15 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantShare option (right to buy) · Derivative | 34,282 | $0.00 Strike: $17.58 | $0.00 |
DisclosureSEC source: 0001209191-21-068956 · doc4.xml · derivative · entry 3 Montalbano John S. · CIK 0001834423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534,282 Underlying: Common Shares · 34,282 shares Expires 2031-08-27 Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 21:47 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 6,000 | $17.23 | $103,380.00 |
DisclosureSEC source: 0001209191-21-051985 · doc4.xml · nonDerivative · entry 1 Montalbano John S. · CIK 0001834423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 01:30 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 5,000 | $20.00 | $100,000.00 |
DisclosureSEC source: 0000899243-20-034341 · doc4.xml · nonDerivative · entry 2 Montalbano John S. · CIK 0001834423 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 5,000 Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 01:30 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | PurchaseCommon Shares | 20,000 | $20.00 | $400,000.00 |
DisclosureSEC source: 0000899243-20-034341 · doc4.xml · nonDerivative · entry 1 Montalbano John S. · CIK 0001834423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| November 18, 2020 Filed Dec 18, 2020 01:30 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $2.41 | $0.00 |
DisclosureSEC source: 0000899243-20-034341 · doc4.xml · derivative · entry 3 Montalbano John S. · CIK 0001834423 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Shares · 500,000 shares Expires 2030-11-18 F1 · derivative.exercise_price: On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. F2 · derivative.exercise_price: The exercise price reported above was converted from the Canadian exercise price of CAD $3.52 using an exchange rate of CAD $1.27840 = US $1.00. F4 · kind: This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F1 · shares: On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. F3 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in equal installments over a four-year period, with the first tranche vesting on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date. F1 · derivative.underlying_shares: On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. F1 · balance_after: On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares ("Stock Split"). This amount has been adjusted to give effect to the Stock Split. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.